| アブストラクト | A 2018 manufacturer post-licensure safety study identified a possible association between Rotarix (RV1) rotavirus vaccine and lower respiratory tract infections (LRTI) in infants within 0-6 days following receipt of RV1 dose 1. We reviewed reports to the Vaccine Adverse Event Reporting System (VAERS) of LRTI occurring 0-6 days and 0-29 days post vaccination following RotaTeq (RV5) or Rotarix (RV1) vaccinations in conjunction with either Prevnar (PCV7) or Prevnar 13 (PCV13), in infants aged 6 to 15 weeks. There was no significant difference in LRTI reports to VAERS in the 0-6 days and 0-29 days following receipt of either RV5 or RV1 given with either pneumococcal vaccine. |
|---|
| 投稿日 | 2018/7/12 |
|---|
| 投稿者 | Haber, Penina; Amin, Muhammad; Ng, Carmen; Weintraub, Eric; McNeil, Michael M |
|---|
| ジャーナル名 | Human vaccines & immunotherapeutics |
|---|
| 組織名 | a Immunization Safety Office, Centers for Disease Control and Prevention ,;Atlanta , GA , USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29993327/ |
|---|
